Skin Manifestations of Allergy

Similar documents
Todd A. Meyer, DO, FAOCO, FAAOA

Children s Hospital Of Wisconsin

What is atopic dermatitis?

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)

Professor Rohan Ameratunga Clinical Immunologist and Allergist Auckland

UPDATES IN ATOPIC DERMATITIS

Dermatitis (inflammatory skin condition) Nonallergic. dermatitis. Non-atopic eczema (non- IgE mediated)

RELEVANT DISCLOSURES ATOPIC DERMATITIS / ECZEMA MANAGING ECZEMA IN INFANTS AND CHILDREN

ATOPIC DERMATITIS: A BLUEPRINT FOR SUCCESS. Sierra Wolter MD, FAAD Pediatric Dermatology University of Arizona, College of Medicine

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

Atopic Eczema with detail on how to apply wet wraps

The Itch That Rashes. Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018

Eczema & Dermatitis Clinical features: Histopathological features: Classification:

過敏病科中心. Allergy Centre. Eczema. Allergy Centre 過敏病科中心. Allergy Centre. For enquiries and appointments, please contact us at:

Pharmacy Benefit Determination Policy

Understanding. Atopic Dermatitis. National Jewish Health. An educational health series from

Skin Deep: Or is It? Practical Pearls from a Pediatric Dermatologist

Assessing the Current Treatment of Atopic Dermatitis: Unmet Needs

An Everyday Guide to Eczema

Pharmacologic Treatment of Atopic Dermatitis

Atopic Dermatitis: Therapeutic Challenges

15 minute eczema consultation

Advisor. Atopic Dermatitis. The Asthma. enter. The Cycle of. Education and Research Fund

ATOPIC DERMATITIS: PATHOPHYSIOLOGY AND PHARMACOLOGY OF MANAGEMENT PEGGY VERNON, RN, MA, C-PNP, DCNP, FAANP

The skin is the largest organ of the human body. Functions: protection sensation maintain temperature vitamin synthesis

Contact Dermatitis In Atopic Patients

Learning Circle: Jan 26, 2011 Childhood Eczema

Drug allergy and Skin Disorders. Timothy Craig, DO, FACOI Professor of Medicine and Pediatrics Distinguished Educator Penn State University, Hershey

Eucrisa. Eucrisa (crisaborole) Description

Allergic Disorders. Allergic Disorders. IgE-dependent Release of Inflammatory Mediators. TH1/TH2 Paradigm

Allergic Disorders. Allergic Disorders. IgE-dependent Release of Inflammatory Mediators. TH1/TH2 Paradigm

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Constitutional eczema

New Medicine Report. Pimecrolimus. RED- Hospital only Date of Last Revision 6 th March 2003

Eucrisa. Eucrisa (crisaborole) Description

Eczema. Most kids get itchy rashes at one time or another. But eczema can be a nuisance that may prompt scratching that makes the problem worse.

Biologic Therapies for Atopic Dermatitis and Beyond

CHAPTER 1. Eczema Basics

Comparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis

Paediatric Eczema. Dr Manjeet Joshi Consultant Dermatologist 16 th May 2012

A Child with Eczema: A Parent s Guide

Clinico Pathological Test SCPA605-Essential Pathology

Managing and Minimizing Flare-ups in Atopic Dermatitis

TRIGGERS & TREATMENT OF ATOPIC DERMATITIS COA#PCIA0809 CE Activity provided by PCI Journal

TCIs are only available on prescription and are usually started by a dermatology specialist.

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:

ATOPIC ECZEMA. What are the aims of this leaflet?

COMMON SKIN CONDITIONS IN PRIMARY CARE. Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio

The Itch That Rashes : An Update on Atopic Dermatitis

Recommended management of eczema in older patients

Diagnosis and Optimal Management of Atopic Dermatitis in the Pediatric Primary Care Setting

5007 Seminar Advanced Therapeutics: Managing Severe & Refractory Eczema. Part 1. Keys to Adherence: Simplify regimen & Educate

My Algorithm. Questions to ask. Do you or your family have a history of?... Allergic rhinitis, Sensitive skin, Asthma Skin Cancer

See Important Reminder at the end of this policy for important regulatory and legal information.

Diagnosis and Management of Common and Infective Skin Diseases in Children at primary care level

What s Topical About Topicals?

ATOPIC DERMATITIS: PATHOPHYSIOLOGY AND PHARMACOLOGY OF MANAGEMENT PEGGY VERNON, RN, MA, C-PNP, DCNP, FAANP

Thursday, 21 October :53 - Last Updated Thursday, 11 November :27

What you need to know about ECZEMA

What you need to know about ECZEMA

Managing Atopic Derma00s: Itching the Night Away. Karol Timmons RN, MS, CPNP Boston Children s Hospital Atopic Derma00s Center

Conflicts of interest

Recommended diagnosis and management of atopic eczema

Comparison of representative topical corticosteroid preparations (classified according to the US system)

Contact Dermatitis Challenges for the General Dermatologist. Susan Nedorost, MD

Associate Professor Rohan Ameratunga

Atopic Dermatitis. Marcia Hogeling, MD Pediatric Dermatologist Phoenix Children s Hospital

Vulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough

Allergy Medications. Antihistamines. are very safe. Although usually taken as tablets, they may be prescribed as a liquid or syrup for young children

Atopic Dermatitis Topics discussed

Atopic dermatitis: tacrolimus vs. topical corticosteroid use

Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript

The Epidemiology of Atopic Dermatitis at a Tertiary Referral Skin Center in Singapore

Management of eczema in infants and children Assoc Prof David Orchard Director, Department of Dermatology Royal Children s Hospital

ATOPIC DERMATITIS IN CHILDREN. Simple choice questions

IMMUNODEFICIENCIES PRIMARY ALLERGIES PRIMARY IMMUNODEFICIENCIES AND ALLERGIES

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

Eczema. By:- Dr. Naif Al-Shahrani Salman bin Abdazziz University

50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate).

Note: AD stands for Atopic Dermatitis. Page numbers in italics indicate figures. Page numbers followed by a t indicate tables.

Topical Immunomodulator Step Therapy Program

Clinical guideline Published: 12 December 2007 nice.org.uk/guidance/cg57

The Medical Letter. on Drugs and Therapeutics

Kelly H. Tyler, MD, FACOG, FAAD S052 Gender Dermatology: Diagnosis and Treatment of Genital Skin Disorders Vulvar Dermatitis

Psoriasis: Causes, Symptoms, And Treatment

Atopic Dermatitis. Atopic dermatitis (AD) is very common with a. Going Skin Deep With. Carl s rashes

8-year surveillance 2016 Atopic eczema in under 12s (2007) NICE guideline CG57

Itchy babies: Current treatment guidelines for atopic dermatitis

Dermatology elective for yr. 5. Natta Rajatanavin, MD. Div. of dermatology Dep. Of Medicine, Ramathibodi Hospital Mahidol University 23 rd Feb 2015

Atopic dermatitis Tacrolimus vs topical corticosteroid use

Atopic Dermatitis and Topical Antipsoriatics

Atopic dermatitis Usually starts t in early infancy Xerosis (dry skin) Pruritus Eczematous lesions

Allergic versus Contact

Phototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])

See Important Reminder at the end of this policy for important regulatory and legal information.

Dupixent (dupilumab)

Topical Calcipotriol Algorithm

Beacon Hospital Annual Study Morning Treatment of Atopic Dermatitis (Eczema) in Primary Care

What to do when patch testing is negative?

Transcription:

Dermatologic Manifestations of Allergy William Reisacher MD FACS FAAOA Assistant Professor Weill Cornell Medical College Skin Manifestations of Allergy Atopic dermatitis (atopic eczema, eczema) Contact dermatitis Angioedema and urticaria You WILL see these Atopic Dermatitis (AD) AD Epidemiology Prevalence 10-20% Children, 1-3% 1 Adults Higher in industrialized nations Higher in urban vs. rural regions More common in higher social class Schultz-Larsen, Immunol Allergy Clin North Am 2002; 22: 1-24 Taylor, Lancet 1984; 2: 1255-57 AD Epidemiology The Atopic March Up to 85% develop symptoms before age 5 Symptoms frequently present in early infancy 45% before 6 months, 60% before age 1 year 30% develop asthma 35% develop allergic rhinitis Atopic Dermatitis seems to be the Entry Point for the development of allergic disease Williams, Atopic Dermatitis, 2000: 41-59 Luoma, Allergy 1983; 38: 339-46 Bustos, Clin Exp Allergy 1995; 25: 568-73

AD Prognosis 60% of AD children are symptom free by early adolescence 50% may recur in adulthood Predictors of persistent disease course: Early onset, severe early disease, asthma and hay fever, and family history Evidence of food and inhalant allergy by age 2 also predicts severe disease AD Clinical Diagnosis Essential Features (3 of 4 Required) Pruritus Facial and extensor eczema in infants and young children / Flexural eczema in older children and adults Chronic or relapsing dermatitis Personal or family history of atopic disease Lammintausta, Int J Dermatol 1991; 30: 563-8 Illi, J Allergy Clin Immunol 2004; 113: 925-31 AD Frequently Associated Features Xerosis Cutaneous infections Chelitis Non-specific dermatitis of hands and feet Elevated serum IgE Positive allergy skin tests Early age at onset Other Possible Features of AD Ichthyosis Palmar Hyperlinearity Other Possible Features of AD Pityriasis alba White dermatographism and delayed blanch response Keratosis Pilaris Anterior subcapsular cataracts, Keratoconus

Other Possible Features of AD Dennie-Morgan infra-orbital folds Orbital Darkening Facial erythema or pallor 3 Phases of Atopic Dermatitis Infantile Phase exudative, erythematous papules and vesicles Face, trunk, extensor surfaces Childhood Phase lichenified papules and plaques Hands, feet, wrists, ankles, antecubital, popliteal Adult Phase dry, scaling, erythematous papules and plaques with large lichenified plaques Flexural folds, face, neck, upper arms, back, dorsa of hands, feet, fingers, and toes Diagnosis of AD is made through history and appearance / distribution of skin lesions! Food and AD Food allergy induces skin rash in 40% of children with AD Can be diagnosed with IPDFT, elimination/challenge or in vitro testing Most commonly egg, milk, wheat, soy, and peanut T-cells specific for foods have been cloned from skin lesions Sampson, J Allergy Clin Immunol 1999; 103: 717-28 Van Reijsen, J Allergy Clin Immunol 1998; 101: 207-09 Food and AD Double-Blind, Placebo Controlled Oral Food Challenges Food allergens caused increased symptoms Symptoms resolved when food was eliminated Sicherer, J Allergy Clin Immunol 1999; 104 Aeroallergens and AD Sensitization to aeroallergens correlates with severity of AD Inhalation challenge in sensitized individuals can exacerbate pruritus and skin lesions Proper avoidance measures in dust sensitive patients has led to improvement in AD Immunotherapy is not universally helpful Recent study showed improved AD when dust allergy is treated with immunotherapy Capristo, Allergy 2004; 59(suppl 78):53-60 Schafer, J Allergy Clin Immunol 1999; 104: 1280-1284 Scalabrin, J Allergy Clin Immunol 1999; 104: 1273-79 Holm, Allergy 2001; 56: 152-58 Werfel, Allergy 2006; 61: 202-205

Aeroallergens and AD Atopy Patch Testing Mostly used for research Occlusive patch testing with aeroallergens elicits eczematoid reactions in 30-50% of AD patients Allergic patients without AD have no reaction to this patch test Auto-allergens and AD Controversial Sera from patients with severe AD may contain IgE antibodies directed against human proteins Mostly intracellular proteins Is AD an autoimmune disease? Wheatley in Leung, Allergic Skin Disease: A Multidisciplinary Approach 2000; 423 Valenta, J Allergy Clin Immunol 2000; 105: 432-37 Staphylococcus aureus and AD Increased colonies of S aureus in 90% of AD skin lesions Improved response to therapy when anti- staph antibiotics are included Superantigen production is the likely mechanism Management of AD Multi-pronged Approach Skin Care Identification and Elimination of Triggers Anti-pruritus Treatment Anti-inflammatory inflammatory Treatment Leyden, Br J Dermatol 1977; 96: 179-87 Breuer, Allergy 2000; 55: 551-55 Skin Care Want to maintain moist skin at all times Soak in clean, warm water (bath, not shower) Avoid soap at every bath Use gentle non-drying soaps (Aveeno, Dove, Basis, Neutrogena) minimal defatting and neutral ph Avoid bath oils Avoid scrub brushes and washcloths Skin Care Pat dry after the bath While skin is still moist, apply an emollient (Aquaphor, Eucerin, Cetaphil, Neutrogena) Petroleum jelly, mineral oil, or Crisco can be used if xerosis is severe

More Skin Care When rash leads to open, oozing sores: Frequent baths (4 per day) in clean, warm water Add colloidal oatmeal to the bath water (3 tbsp) Avoid irritants! Skin Irritants Soaps and detergents Want minimal defatting activity and neutral ph Wash clothes in gentle, liquid detergent and add extra rinse cycle Heat and perspiration Occlusive clothing Loose fitting cotton, silk, and cotton blends are best Sunburn Identification and Elimination of Triggers Identify potential allergens through history and skin testing or in vitro testing Foods are very important and proper elimination / rotation diets should be used Immunotherapy for AD has not been proven to be beneficial Reserve for patients with clear seasonal exacerbations or other symptoms of allergic disease Treat Pruritus Proper bathing and emollients may be enough Add antihistamine if needed Cetirizine, loratadine, desloratadine, fexofenadine, diphenhydramine, hydroxyzine Try non-sedating in morning and sedating at night to help with sleep Topical Doxepin works well, but is sedating Anti-Staphylococcal Medication Topical mupirocin (Bactroban)) works well when Staph colonization is present (almost always) Treat the nose, too! Watch for super-imposed HSV infection Topical Corticosteroids Reduce inflammation and pruritus in acute and chronic AD Goal is to use the lowest strength possible to control symptoms Ointments are generally preferred over cream / gel More occlusive and fewer additives

Topical Corticosteroids Adverse Effects Thinning skin Telangiectasias Bruising Hypopigmentation Acne Striae Face and intertriginous areas are more susceptible to these events Low Potency formulations only! Topical Corticosteroids Least Potent to Most Potent Group 7 Group 3 Hydrocortisone (Hytone) 1 Fluticasone (Cutivate).005% and 2.5% oint/cream oint Group 6 Halcinonide (Halog).1% oint Desonide (DesOwen).05% Betamethasone (Valisone) oint/cream/lotion.1% oint Alclometasone (Aclovate) Group 2.05% oint/cream Mometasone (Elocon).1% Group 5 oint Fluocinolone (Synalar).025% Halcinonide (Halog).1% cream cream Hydrocortisone valerate Fluocinonide (Lidex).05% (Westcort).2% oint oint/cream Group 4 Desoximetasone (Topicort).25% oint/cream Mometasone (Elocon).1% cream Group 1 Fluocinolone (Synalar).025% Betamethasone (Diprolene) oint.05% (ointment, gel) Triamcinolone (Kenalog).1% Clobetasol (Temovate).05% oint/cream oint/cream Prescribe Enough! BID dosing for most, QD for Fluticasone and Mometasone 30g is needed to cover the entire body of an average adult Instruct patients in the FTU (Finger Tip Unit) Medication extends from tip to the first joint of the index finger 1 FTU = Hand or groin, 2 FTU s s = face or foot, 3 FTU s s = arm, 6 FTU s s = leg, 14 FTU s s = trunk Taper the Dose Start with a higher potency steroid for moderate to severe AD When improved after 2 weeks or so step down to a lower potency before stopping If not tapered, AD flares can develop Steroid therapy may be discontinued when inflammation has resolved Continue hydration and emollients Consider twice weekly steroid maintenance Van Der Meer, Br J Dermatol 1999; 140: 1114-1121 Calcineurin Inhibitors Tacrolimus (Protopic) and Pimecrolimus (Elidel) Bind to intracellular immunophilins in T-T cells Inhibits calcineurin a calcium-ion ion-calmodulin dependent protein phosphatase necessary for signal transduction Cytokine gene transcription cannot occur Official Indications for Calcineurin Inhibitors Tacrolimus.03% BID -- Moderate to severe AD, over the age of 2, unresponsive to, or intolerant of, steroids Tacrolimus.1% BID -- As above, over the age of 16 Pimecrolimus 1% BID -- Mild to Moderate AD, over the age of 2, unresponsive to steroids Local burning sensation is common, but usually resolves in 3 days Boguniewicz, J Allergy Clin Immunol 2003; 112: S140-50

Black Box Warning on Calcineurin Inhibitors Threatened Post-marketing reports of malignancy in patients on calcineurin inhibitors Not higher than the general population Primate study with oral pimecrolimus demonstrated development of lymphoma 30x the maximum recommended human dose 2005 ACAAI and AAAAI Calcineurin Inhibitor Task Force Recommend no change in current usage patterns Other Therapies for AD Phototherapy sunlight in small doses, UV-B B and UV-A, and photochemotherapy with psoralen and UV-A A (PUVA) for severe cases Systemic steroids Avoid as much as possible (discontinuing usually associated with flares) Interferon Gamma Downregulate Th2 function Cyclosporin systemic calcineurin inhibitor can improve symptoms, but side effects (renal impairment and HTN) limit its use Fonacier, J Allergy Clin Immunol 2005; 115(6): 1249-53 Other Therapies for AD Antimetabolites Mycophenolate, Methotrexate, Azathioprine Psychological Treatment Emotional stressors exacerbate disease Probiotics 56 infants with mod-severe AD, randomized to lactobacillus or placebo significant improvemnet in probiotic group after 8 weeks Weston, Arch Dis Child 2005; 90: 892-897 Tar Preparations coal tar is anti-pruritic and anti- inflammatory, may induce folliculitis and photosensitivity, use restricted to chronic lesions Atopic Dermatitis Treatment Algorithm - Summary Skin care / emollients Identification and avoidance of irritants / triggers Possible antihistamines / antibiotics If not enough, add low-potency steroid or calcineurin inhibitor Consider Dermatology evaluation Contact Dermatitis Are you itchy yet? Type IV hypersensitivity reaction Genetic contribution Initial sensitization occurs 10-14 days after antigen is picked up by Langerhan s APC Reaction occurs 12-48 hours after subsequent exposure Th1 pattern cytokine response

Contact Dermatitis - Triggers Plant oleoresin (ex. Poison ivy) Nickel and other metals Fragrances, nail polish Rubber, latex products Topical meds: hydrocortisone, Abx, benzocaine, benzaconium chloride Contact Dermatitis - Features May be acute or chronic Intense, pruritic, papular erythematous rash with indistinct margins in contact area May be worse in areas of venous stasis History is critical in the diagnosis Patch testing may be done as well Leaves of three Leave them be! Contact Dermatitis - Treatment Identification of offender & AVOIDANCE! Medium to strong potency topical steroids for limited duration Wet to dry compresses for oozing Calamine lotion, topical antihistamines Systemic steroids and antihistamines for more severe cases